放射性医薬品市場：タイプ別、手術数別、用途別 - 2024年～2030年の世界予測

放射性医薬品市場規模は、2023年に51億5,000万米ドルと推計され、2024年には54億8,000万米ドルに達し、CAGR 6.47%で2030年には80億米ドルに達すると予測されています。

放射性医薬品は、核医学の分野で使用される放射性同位元素を含む医薬製剤のユニークなカテゴリーです。放射線を放出する能力を特徴とするこれらの化合物は、診断、治療、研究など多目的に使用されています。放射性医薬品病気の発見と治療の両面で重要な価値を提供し、早期診断、病気の進行のモニタリング、治療介入の有効性を高める。放射性医薬品は、高度な診断技術を必要とするがんや心血管疾患などの慢性疾患の有病率の上昇に牽引され、大きな普及を経験しています。PETやSPECTなどのイメージング技術の進歩も、放射性医薬品市場の成長を後押ししています。さらに、個別化医療や標的治療アプローチの採用が増加していることも、治療用途における放射性同位元素の需要を押し上げています。かなりの成長が見込まれるもの、放射性医薬品市場は、新規放射性医薬品の承認に時間がかかる厳しい規制要件などの課題に直面しています。放射性医薬品の開発・製造には高いコストがかかり、専門施設や訓練された人材が必要であることも、業界が直面する課題に拍車をかけています。しかし、研究開発への投資の増加は、放射性医薬品市場の革新と拡大のための十分な機会を提供しています。さらに、診断と治療の機能を単一の薬剤に統合するセラノスティクスの進歩は、統合的なヘルスケアソリューションと個別化治療への新たな道を提示し、放射性医薬品市場を持続的成長へと位置づけています。

処置量：ブラキセラピーにおけるアイソトープ治療の進歩

放射性医薬品は診断と治療の両面で、現代医療において極めて重要な役割を担っています。PET放射性医薬品とSPECT放射性医薬品を含む診断手技の手技件数は、正確な疾患検出とモニタリングにおける重要な機能により、依然として重要です。PET検査は陽電子を放出する放射性医薬品を利用し、代謝活動や血流などのプロセスを高分解能で機能的に画像化します。対照的に、SPECT法ではガンマ線を放出する放射性医薬品を使用して生理学的機能をマッピングします。治療手技では、アルファ線放出核種は高い線エネルギー移動と短い飛程により、微小転移の治療に有効です。ベータ線放出核種は、組織への浸透性が高いため、より大量の病変細胞を治療するのに適しています。ブラキセラピー・アイソトープ治療では、放射性線源を腫瘍やその近傍に直接埋め込むため、周囲の健康な組織への影響を最小限に抑えながら局所的な放射線治療を行うことができます。

応用：治療法における放射性医薬品の利用の増加

陽電子放射断層撮影法（PET）は、心筋灌流と代謝の詳細な可視化を可能にすることで、心臓病学において重要な役割を担っています。PETは、冠動脈疾患を含む様々な心臓疾患の診断、心筋の生存能力の評価、治療後の心筋の健康状態のモニタリングに役立っています。神経学では、PETは脳血流、グルコース代謝、アミノ酸取り込みに関する貴重な洞察を提供します。PET画像はパーキンソン病、てんかん、アルツハイマー病などの神経変性疾患の評価に広く利用されています。早期診断、疾患の進行追跡、治療介入の評価に役立つため、個別化された神経学的患者ケアにおいて重要な役割を果たしています。PET画像は、がんを高感度で検出し、病期を決定する能力があるため、腫瘍学において極めて重要です。腫瘍の位置の特定、代謝活性の把握、治療に対する反応の評価などに役立っています。PET検査は、外科的治療計画、放射線治療、新しい化学療法レジメンの評価など、がん治療における臨床的意思決定の指針となり、腫瘍学的介入への道を提供します。

単一光子放射型コンピュータ断層撮影は、血流を評価し、心臓のポンプ機能を調べるために、心臓画像診断で一般的に使用されています。虚血や梗塞の部位を検出し、臨床医の介入計画を支援します。SPECT画像はリンパ腫患者の病期分類と経過観察において重要な役割を担っています。SPECTはリンパ節の正確な位置の特定と病気の広がりを評価することができ、これは治療法を調整するのに非常に重要です。神経学では、SPECTは脳血流を分析し、神経細胞の完全性を評価することができます。脳卒中、認知症、発作性障害などの疾患の評価に使用され、機能障害や治療効果の判定に役立っています。SPECTは特に甲状腺の画像診断に有効で、結節の存在や性質を評価したり、甲状腺機能亢進症の症例に用いられます。甲状腺の活動性に関する機能的な情報を提供し、術後の評価や転移の検出など、甲状腺がん患者の管理に役立ちます。

放射性医薬品は、転移がん細胞が骨に広がっている骨転移の緩和治療に極めて重要な役割を果たします。ストロンチウム-89やサマリウム-153などの放射性化合物を患者に投与し、骨のターンオーバーが亢進している部位に選択的に局在させ、局所放射線を照射することで、痛みを緩和し、オピオイド鎮痛薬の必要性を減らすことができます。神経内分泌腫瘍（NET）などの内分泌腫瘍の管理は、放射性医薬品の使用によって一変しました。ルテチウム-177ドタテートなどの放射性標識ソマトスタチン類似体を用いたペプチド受容体放射性核種治療（PRRT）は、腫瘍細胞上のソマトスタチン受容体を標的として、腫瘍に直接細胞毒性放射線を照射します。リンパ腫、特に非ホジキンリンパ腫（NHL）に対する放射性医薬品治療は、悪性細胞表面のCD20抗原を標的とする放射性標識モノクローナル抗体を組み込んだものです。イットリウム90を結合させたイブリツモマブ・チウキセタン（ゼヴァリン）などの薬剤は、がん細胞に標的放射線治療を行い、従来の化学療法に抵抗性の患者や、より攻撃性の低い治療法を求める患者に有効な反応をもたらします。ヨウ素131による放射性ヨウ素治療は、甲状腺機能亢進症や分化型甲状腺がんに対する確立された治療法です。この標的アプローチは、分化型甲状腺がんの術後管理に極めて重要であり、治療と画像診断の両方に役立ちます。

地域別インサイト

南北アメリカの放射性医薬品市場は、核医学の進歩と先進ヘルスケアインフラに牽引され、力強い成長を示しています。米国は、研究開発への多額の投資と有利な償還政策により、市場に大きく貢献しています。カナダとラテンアメリカも、認知度の向上とヘルスケア施設の改善により、ペースは遅いもの成長を遂げています。欧州はEMEA地域の中でも放射性医薬品市場に大きく貢献しており、慢性疾患の罹患率の上昇、高齢化、ヘルスケア支出の増加などが普及を後押ししています。ドイツ、フランス、英国は、先進的なヘルスケアシステムと政府の支援策により、市場で確固たる地位を築いています。中東とアフリカは未開拓の可能性を秘めた新興市場であり、ヘルスケア・インフラへの投資が増加し、診断サービスへの需要が高まっていることが特徴です。しかし、熟練した専門家の不足や国ごとの経済的なばらつきが、この地域での市場拡大の課題となる可能性があります。アジア太平洋地域の放射性医薬品市場は急速な成長を遂げており、進化するヘルスケア分野における強力な研究基盤が大きな成長機会をもたらしています。中国、日本、オーストラリア、韓国などの国々がこの成長の最前線にあります。ヘルスケアの近代化に向けた政府の取り組みが活発化していることも、市場開拓を後押ししています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは放射性医薬品市場の評価において極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、放射性医薬品市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.放射性医薬品市場の市場規模および予測は？

2.放射性医薬品市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.放射性医薬品市場の技術動向と規制枠組みは？

4.放射性医薬品市場における主要ベンダーの市場シェアは？

5.放射性医薬品市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 対象疾患の発生率と有病率の増加
    • アルファ放射免疫療法に基づく標的がん治療
    • mo-99の需給ギャップを縮小するための取り組み
  • 抑制要因
    • 放射性医薬品の寿命が短くなる
  • 機会
    • 神経学アプリケーションにおける放射性医薬品の採用
    • 診断センターの増加、特に新興諸国で増加
  • 課題
    • 高額な機器価格と限られた病院予算
• 市場セグメンテーション分析
  • 手術数：密封小線源治療同位元素手順の継続的な進歩
  • 用途：治療手順における放射性医薬品の利用率の向上
• 市場動向分析
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析
• 顧客のカスタマイズ

第6章 放射性医薬品市場：タイプ別

• 核医学診断
• 核医学治療

第7章 放射性医薬品市場：手術数別

• 診断
• 治療

第8章 放射性医薬品市場：用途別

• 診断用途
• 治療用途

第9章 南北アメリカの放射性医薬品市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の放射性医薬品市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの放射性医薬品市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • ブリストルマイヤーズスクイブ、レイズバイオの買収によりプレミア放射性医薬品プラットフォームを追加
  • 新しいCRPが病気の診断のための新しいテクネチウム99m放射性医薬品を開発
  • メイヨー・クリニックの支援を受けたスタートアップが5,600万米ドルを調達し、放射性医薬品の障害に狙いを定める

第13章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. RADIOPHARMACEUTICALS MARKET RESEARCH PROCESS
• FIGURE 2. RADIOPHARMACEUTICALS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. RADIOPHARMACEUTICALS MARKET DYNAMICS
• FIGURE 7. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 14. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 16. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. RADIOPHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 22. RADIOPHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. RADIOPHARMACEUTICALS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY F-18, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY F-18, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RU-82, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RU-82, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GA-67, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GA-67, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY I-123, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY I-123, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TC-99M, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TC-99M, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TL-201, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TL-201, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY I-131, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY I-131, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LU-177, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LU-177, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RE-186, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RE-186, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SM-153, BY REGION, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SM-153, BY REGION, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY Y-90, BY REGION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY Y-90, BY REGION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2024-2030 (USD MILLION)
• TABLE 57. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CS-131, BY REGION, 2018-2023 (USD MILLION)
• TABLE 58. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CS-131, BY REGION, 2024-2030 (USD MILLION)
• TABLE 59. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY I-125, BY REGION, 2018-2023 (USD MILLION)
• TABLE 60. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY I-125, BY REGION, 2024-2030 (USD MILLION)
• TABLE 61. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY IR-192, BY REGION, 2018-2023 (USD MILLION)
• TABLE 62. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY IR-192, BY REGION, 2024-2030 (USD MILLION)
• TABLE 63. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PD-103, BY REGION, 2018-2023 (USD MILLION)
• TABLE 64. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PD-103, BY REGION, 2024-2030 (USD MILLION)
• TABLE 65. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2018-2023 (USD MILLION)
• TABLE 66. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2024-2030 (USD MILLION)
• TABLE 67. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 68. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 69. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2023 (USD MILLION)
• TABLE 70. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2024-2030 (USD MILLION)
• TABLE 71. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICAL PROCEDURE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 72. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICAL PROCEDURE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 73. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS PROCEDURE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 74. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS PROCEDURE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 75. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 76. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 77. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2018-2023 (USD MILLION)
• TABLE 78. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2024-2030 (USD MILLION)
• TABLE 79. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ALPHA EMITTER PROCEDURE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 80. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ALPHA EMITTER PROCEDURE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 81. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS PROCEDURE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 82. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS PROCEDURE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 83. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES PROCEDURE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 84. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES PROCEDURE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 85. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 86. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 87. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 88. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 89. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 90. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 91. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 92. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 93. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 94. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 95. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY INDICATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 96. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY INDICATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 97. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY INDICATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 98. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY INDICATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 99. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY INDICATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 100. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY INDICATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 101. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 102. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 103. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 104. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 105. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 106. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 107. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 108. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LYMPHOMA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 109. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 110. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 111. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THYROID, BY REGION, 2018-2023 (USD MILLION)
• TABLE 112. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THYROID, BY REGION, 2024-2030 (USD MILLION)
• TABLE 113. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 114. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 115. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 116. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 117. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BONE METASTASIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 118. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BONE METASTASIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 119. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ENDOCRINE TUMORS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 120. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ENDOCRINE TUMORS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 121. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LYMPHOMA THERAPEUTIC, BY REGION, 2018-2023 (USD MILLION)
• TABLE 122. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LYMPHOMA THERAPEUTIC, BY REGION, 2024-2030 (USD MILLION)
• TABLE 123. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THYROID THERAPEUTIC, BY REGION, 2018-2023 (USD MILLION)
• TABLE 124. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THYROID THERAPEUTIC, BY REGION, 2024-2030 (USD MILLION)
• TABLE 125. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 126. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 127. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
• TABLE 128. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
• TABLE 129. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
• TABLE 130. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
• TABLE 131. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
• TABLE 132. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
• TABLE 133. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
• TABLE 134. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
• TABLE 135. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2018-2023 (USD MILLION)
• TABLE 136. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2024-2030 (USD MILLION)
• TABLE 137. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2023 (USD MILLION)
• TABLE 138. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2024-2030 (USD MILLION)
• TABLE 139. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2018-2023 (USD MILLION)
• TABLE 140. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2024-2030 (USD MILLION)
• TABLE 141. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2023 (USD MILLION)
• TABLE 142. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2024-2030 (USD MILLION)
• TABLE 143. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2018-2023 (USD MILLION)
• TABLE 144. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2024-2030 (USD MILLION)
• TABLE 145. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 146. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 147. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 148. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 149. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 150. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 151. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 152. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 153. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 154. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 155. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 156. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 157. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 158. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 159. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
• TABLE 160. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
• TABLE 161. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
• TABLE 162. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
• TABLE 163. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
• TABLE 164. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
• TABLE 165. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
• TABLE 166. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
• TABLE 167. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2018-2023 (USD MILLION)
• TABLE 168. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2024-2030 (USD MILLION)
• TABLE 169. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2023 (USD MILLION)
• TABLE 170. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2024-2030 (USD MILLION)
• TABLE 171. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2018-2023 (USD MILLION)
• TABLE 172. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2024-2030 (USD MILLION)
• TABLE 173. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2023 (USD MILLION)
• TABLE 174. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2024-2030 (USD MILLION)
• TABLE 175. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2018-2023 (USD MILLION)
• TABLE 176. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2024-2030 (USD MILLION)
• TABLE 177. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 178. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 179. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 180. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 181. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 182. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 183. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 184. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 185. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 186. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 187. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 188. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 189. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
• TABLE 190. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
• TABLE 191. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
• TABLE 192. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
• TABLE 193. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
• TABLE 194. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
• TABLE 195. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
• TABLE 196. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
• TABLE 197. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2018-2023 (USD MILLION)
• TABLE 198. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2024-2030 (USD MILLION)
• TABLE 199. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2023 (USD MILLION)
• TABLE 200. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2024-2030 (USD MILLION)
• TABLE 201. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2018-2023 (USD MILLION)
• TABLE 202. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2024-2030 (USD MILLION)
• TABLE 203. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2023 (USD MILLION)
• TABLE 204. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2024-2030 (USD MILLION)
• TABLE 205. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2018-2023 (USD MILLION)
• TABLE 206. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2024-2030 (USD MILLION)
• TABLE 207. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 208. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 209. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 210. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 211. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 212. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 213. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 214. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 215. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 216. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 217. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 218. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 219. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
• TABLE 220. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
• TABLE 221. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
• TABLE 222. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
• TABLE 223. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
• TABLE 224. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
• TABLE 225. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
• TABLE 226. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
• TABLE 227. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2018-2023 (USD MILLION)
• TABLE 228. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2024-2030 (USD MILLION)
• TABLE 229. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2023 (USD MILLION)
• TABLE 230. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2024-2030 (USD MILLION)
• TABLE 231. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2018-2023 (USD MILLION)
• TABLE 232. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2024-2030 (USD MILLION)
• TABLE 233. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2023 (USD MILLION)
• TABLE 234. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2024-2030 (USD MILLION)
• TABLE 235. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2018-2023 (USD MILLION)
• TABLE 236. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2024-2030 (USD MILLION)
• TABLE 237. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 238. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 239. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 240. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 241. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 242. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 243. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 244. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 245. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 246. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 247. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 248. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 249. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
• TABLE 250. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
• TABLE 251. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
• TABLE 252. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
• TABLE 253. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
• TABLE 254. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
• TABLE 255. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
• TABLE 256. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
• TABLE 257. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2018-2023 (USD MILLION)
• TABLE 258. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2024-2030 (USD MILLION)
• TABLE 259. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2023 (USD MILLION)
• TABLE 260. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2024-2030 (USD MILLION)
• TABLE 261. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2018-2023 (USD MILLION)
• TABLE 262. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2024-2030 (USD MILLION)
• TABLE 263. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2023 (USD MILLION)
• TABLE 264. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2024-2030 (USD MILLION)
• TABLE 265. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2018-2023 (USD MILLION)
• TABLE 266. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2024-2030 (USD MILLION)
• TABLE 267. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 268. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 269. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 270. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 271. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 272. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 273. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 274. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 275. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 276. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 277. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 278. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 279. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
• TABLE 280. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
• TABLE 281. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
• TABLE 282. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
• TABLE 283. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
• TABLE 284. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
• TABLE 285. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
• TABLE 286. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
• TABLE 287. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2018-2023 (USD MILLION)
• TABLE 288. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2024-2030 (USD MILLION)
• TABLE 289. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2023 (USD MILLION)
• TABLE 290. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2024-2030 (USD MILLION)
• TABLE 291. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2018-2023 (USD MILLION)
• TABLE 292. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2024-2030 (USD MILLION)
• TABLE 293. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2023 (USD MILLION)
• TABLE 294. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2024-2030 (USD MILLION)
• TABLE 295. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2018-2023 (USD MILLION)
• TABLE 296. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2024-2030 (USD MILLION)
• TABLE 297. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 298. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 299. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 300. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 301. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 302. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 303. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 304. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 305. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 306. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 307. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 308. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 309. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 310. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 311. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
• TABLE 312. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
• TABLE 313. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
• TABLE 314. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
• TABLE 315. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
• TABLE 316. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
• TABLE 317. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
• TABLE 318. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
• TABLE 319. ASIA-PACIFIC

[191 Pages Report] The Radiopharmaceuticals Market size was estimated at USD 5.15 billion in 2023 and expected to reach USD 5.48 billion in 2024, at a CAGR 6.47% to reach USD 8.00 billion by 2030.

Radiopharmaceuticals are a unique category of medicinal formulations containing radioisotopes that are used in the field of nuclear medicine. These compounds, which are characterized by their ability to emit radiation, serve multiple purposes, including diagnosis, therapy, and research. Radiopharmaceuticals offer significant value in both the detection and treatment of disease, enhancing the capability for early diagnosis, monitoring of disease progression, and effectiveness of therapeutic interventions. Radiopharmaceutical compounds are experiencing significant adoption, driven by the rising prevalence of chronic diseases such as cancer and cardiovascular disorders that require advanced diagnostic techniques. Technological advancements in imaging technologies, such as PET and SPECT, are also catalyzing the radiopharmaceuticals market growth. Additionally, the increasing adoption of personalized medicine and targeted therapy approaches boosts the demand for radioisotopes in therapeutic applications. Despite considerable growth prospects, the radiopharmaceuticals market faces challenges, including stringent regulatory requirements that result in longer approval times for new radiopharmaceuticals. High costs for radiopharmaceutical development and production, as well as the requirement for specialized facilities and trained personnel, add to the list of challenges facing the industry. However, the increasing investment in research and development provides ample opportunities for innovation and expansion in the radiopharmaceutical market. Furthermore, ongoing advancements in theranostics, which combine diagnostic and therapeutic capabilities in a single agent, present new avenues for integrative healthcare solutions and personalized treatment, positioning the radiopharmaceuticals market for sustained growth.

Procedural Volume: Ongoing advancements in brachytherapy isotopes procedure

Radiopharmaceuticals play a pivotal role in modern medicine, both in diagnostics and therapy. The procedural volume for diagnostic procedures, including PET radiopharmaceuticals and SPECT radiopharmaceuticals, remains significant, owing to their critical function in accurate disease detection and monitoring. PET procedures utilize positron-emitting radiopharmaceuticals, providing high-resolution, functional imaging of processes such as metabolic activity or blood flow. In contrast, SPECT procedures involve gamma-emitting radiopharmaceuticals for mapping physiological functions. In therapeutic procedures, alpha emitters offer advantages owing to the high linear energy transfer and short range, making them effective in treating micrometastases. Beta emitter procedures are more recognized for treating larger volumes of diseased cells due to their broader tissue penetration. Brachytherapy isotope procedures involve implanting radioactive sources directly into or near a tumor, thus delivering localized radiation therapy with minimal impact on surrounding healthy tissue.

Application: Increasing utilization of radiopharmaceuticals in therapeutic procedures

Positron emission tomography (PET) has a crucial role in cardiology by enabling detailed visualization of myocardial perfusion and metabolism. It aids in diagnosing various heart conditions, including coronary artery disease, evaluating myocardial viability, and monitoring heart muscle health post-intervention. In neurology, PET provides valuable insights into cerebral blood flow, glucose metabolism, and amino acid uptake. PET imaging is widely utilized in the evaluation of neurodegenerative diseases, such as Parkinson's disease, epilepsy, and Alzheimer's disease. It aids in early diagnosis, tracking disease progression, and assessing therapeutic interventions, thereby playing a significant role in personalized neurological patient care. PET imaging is crucial in oncology due to its ability to detect and stage cancer with high sensitivity. It assists in pinpointing the location of tumors, understanding their metabolic activity, and evaluating responses to therapy. PET scans guide clinical decision-making in cancer treatment, including surgical planning, radiation therapy, and the assessment of new chemotherapy regimes, thereby offering a path to tailored oncologic interventions.

Single photon emission computed tomography is commonly used in cardiac imaging to evaluate blood flow and examine the pumping function of the heart. It detects areas of ischemia and infarction, assisting clinicians with intervention planning. SPECT imaging has a significant role in the staging and follow-up of lymphoma patients. It allows for the precise localization of lymph nodes and assessment of the disease spread, which is crucial for tailoring the treatment approach. In neurology, SPECT can analyze cerebral blood flow and assess neuronal integrity. It is used in the evaluation of disorders such as stroke, dementia, and seizure disorders, aiding in the determination of functional impairment and treatment efficacy. SPECT is particularly effective in thyroid imaging to evaluate the presence and nature of nodules and in cases of hyperthyroidism. It provides functional information about thyroid activity and assists in the management of thyroid cancer patients, including post-surgical assessment and detection of metastases.

Radiopharmaceuticals play a pivotal role in the palliative treatment of bone metastasis, where metastatic cancer cells have spread to bones. These radioactive compounds, such as Strontium-89 and Samarium-153, are administered to patients, where they selectively localize to areas of increased bone turnover, emitting local radiation that alleviates pain and can reduce the need for opioid analgesics, thereby improving the quality of life in patients with advanced cancers. The management of endocrine tumors, such as neuroendocrine tumors (NETs), has been transformed by the use of radiopharmaceuticals. Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs, such as Lutetium-177 dotatate, targets somatostatin receptors on tumor cells to deliver cytotoxic radiation directly to the tumor, minimizing the exposure to surrounding healthy tissue and offering an effective therapeutic option for inoperable or metastasized NETs. Radiopharmaceutical therapy for lymphoma, particularly non-Hodgkin lymphoma (NHL), incorporates radiolabeled monoclonal antibodies that target CD20 antigens on the surface of malignant cells. Agents such as Ibritumomab Tiuxetan (Zevalin) conjugated with Yttrium-90 deliver targeted radiotherapy to the cancerous cells, which can result in an effective response for patients with refractory to conventional chemotherapy or for those seeking a less aggressive treatment. Radioiodine therapy with Iodine-131 is a well-established treatment for hyperthyroidism and differentiated thyroid cancer. This targeted approach is crucial for differentiated thyroid carcinoma management post-surgery, aiding in both treatment and diagnostic imaging.

Regional Insights

The radiopharmaceutical market in the Americas has shown robust growth, driven by advancements in nuclear medicine and the advanced healthcare infrastructure. The United States contributes majorly to the market with its substantial investments in R&D and favorable reimbursement policies. Canada and Latin America are also experiencing growth, albeit at a slower pace, owing to increasing awareness and improving healthcare facilities. Europe is a significant contributor to the radiopharmaceutical market within the EMEA region, with adoption fuelled by the rising incidence of chronic illnesses, the aging population, and increased healthcare expenditure. Germany, France, and the UK have strong market positions due to their advanced healthcare systems and supportive government initiatives. The Middle East and Africa are emerging markets with untapped potential, characterized by increasing investment in healthcare infrastructure and a growing demand for diagnostic services. However, the scarcity of skilled professionals and economic variability across countries may challenge market expansion in this region. The Asia-Pacific radiopharmaceutical market is experiencing rapid growth, offering substantial opportunities due to its strong research base in evolving healthcare sectors. Countries such as China, Japan, Australia, and South Korea are at the forefront of this growth. The increasing government initiatives to modernize healthcare are propelling market development.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Radiopharmaceuticals Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Radiopharmaceuticals Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Radiopharmaceuticals Market, highlighting leading vendors and their innovative profiles. These include Alliance Holdings Medical Limited, Bayer AG, Bracco Group, BWX Technologies. Inc., BWXT Medical Ltd., Cardinal Health, Inc., Clarity Pharmaceuticals, Curium Pharma, Eckert & Ziegler Group, Eczacibasi-Monrol Nuclear Products Co., Fusion Pharmaceuticals Inc., GE HealthCare Technologies, Inc., Global Medical Solutions, Institute of Isotopes Co. Ltd., International Isotopes, Inc., IsoTherapeutics Group, LLC, Isotopia Molecular Imaging Ltd., Jubilant Pharma Holdings Inc., Lantheus Medical Imaging, Inc., Mallinckrodt PLC, Medi-Radiopharma, Northstar Medical Technologies LLC, Novartis AG, NTP Radioisotopes SOC Ltd., SHINE Medical Technologies, Siemens Healthineers AG, Sinotau Pharmaceutical Group, and State Atomic Energy Corporation Rosatom.

Market Segmentation & Coverage

This research report categorizes the Radiopharmaceuticals Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Type
  • Diagnostic Nuclear Medicine
    • Pet Radiopharmaceuticals
      • F-18
      • Ru-82

• Spect Radiopharmaceuticals
  • Ga-67
  • I-123
  • Tc-99m
  • Tl-201
• Therapeutic Nuclear Medicine
  • Alpha Emitters
  • Beta Emitters
    • I-131
    • Lu-177
    • Re-186
    • Sm-153
    • Y-90

• Brachytherapy Isotopes
  • Cs-131
  • I-125
  • Ir-192
  • Pd-103
• Procedural Volume
  • Diagnostic Procedures
    • Pet Radiopharmaceutical Procedure
    • Spect Radiopharmaceuticals Procedure

• Therapeutic Procedures
  • Alpha Emitter Procedure
  • Beta Emitters Procedure
  • Brachytherapy Isotopes Procedure
• Application
  • Diagnostic Applications
    • Pet Applications
      • Cardiology Indication
      • Neurology Indication
      • Oncology Indication

• Spect Applications
  • Cardiology
  • Lymphoma
  • Neurology
  • Thyroid
• Therapeutic Applications
  • Bone Metastasis
  • Endocrine Tumors
  • Lymphoma Therapeutic
  • Thyroid Therapeutic
• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Radiopharmaceuticals Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Radiopharmaceuticals Market?

3. What are the technology trends and regulatory frameworks in the Radiopharmaceuticals Market?

4. What is the market share of the leading vendors in the Radiopharmaceuticals Market?

5. Which modes and strategic moves are suitable for entering the Radiopharmaceuticals Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing Incidence and Prevalence of Target Conditions
    • 5.1.1.2. Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
    • 5.1.1.3. Initiatives To Reduce The Demand-Supply Gap of mo-99
  • 5.1.2. Restraints
    • 5.1.2.1. Shorter Life of Radiopharmaceuticals
  • 5.1.3. Opportunities
    • 5.1.3.1. Adoption of Radiopharmaceuticals in Neurological Applications
    • 5.1.3.2. Rising Number of Diagnostic Centers Especially in Developing Countries
  • 5.1.4. Challenges
    • 5.1.4.1. High Equipment Prices and Limited Hospital Budget
• 5.2. Market Segmentation Analysis
  • 5.2.1. Procedural Volume: Ongoing advancements in brachytherapy isotopes procedure
  • 5.2.2. Application: Increasing utilization of radiopharmaceuticals in therapeutic procedures
• 5.3. Market Trend Analysis
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework Analysis
• 5.9. Client Customization

6. Radiopharmaceuticals Market, by Type

• 6.1. Introduction
• 6.2. Diagnostic Nuclear Medicine
• 6.3. Therapeutic Nuclear Medicine

7. Radiopharmaceuticals Market, by Procedural Volume

• 7.1. Introduction
• 7.2. Diagnostic Procedures
• 7.3. Therapeutic Procedures

8. Radiopharmaceuticals Market, by Application

• 8.1. Introduction
• 8.2. Diagnostic Applications
• 8.3. Therapeutic Applications

9. Americas Radiopharmaceuticals Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Radiopharmaceuticals Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Radiopharmaceuticals Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
  • 12.3.2. New CRP to Develop new Technetium-99m Radiopharmaceuticals for Disease Diagnosis
  • 12.3.3. With USD 56 Million, a Mayo Clinic-backed Startup takes aim at Radiopharmaceutical Roadblocks

13. Competitive Portfolio

• 13.1. Key Company Profiles
• 13.2. Key Product Portfolio